BioCentury | Jan 13, 2017
Clinical News

Oral Debio 1450: Ph II data

...Molecular target: fabI enoyl-(acyl carrier protein) reductase Description: Oral formulation of a small molecule prodrug inhibitor of the bacterial fabI enoyl-(acyl carrier protein) reductase...
...after 7-14 days of treatment Status: Phase II data Milestone: NA Jaime De Leon oral Debio 1450 Debiopharm Group fabI enoyl-(acyl carrier protein) reductase...
BioCentury | Jan 13, 2017
Clinical News

IV Debio 1450: Ph II data

...Molecular target: fabI enoyl-(acyl carrier protein) reductase Description: IV formulation of a small molecule prodrug inhibitor of the bacterial fabI enoyl-(acyl carrier protein) reductase...
...after 7-14 days of treatment Status: Phase II data Milestone: NA Jaime De Leon IV Debio 1450 Debiopharm Group fabI enoyl-(acyl carrier protein) reductase...
BioCentury | Jan 10, 2017
Clinical News

Debiopharm antibiotic passes Phase II ABSSSI test

...with FDA's 2013 final guidance (see BioCentury Extra, Oct. 17, 2013) . Jaime De Leon Debio 1450 Debiopharm Group fabI enoyl-(acyl carrier protein) reductase...
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

...kidneys. The company’s most advanced clinical program is CG400549 , a potentially first-in-class antibiotic targeting fabI enoyl-(acyl carrier protein) reductase...
BioCentury | Mar 21, 2016
Product Development

Korea rising

...skin structure infections and to treat vancomycin-resistant Staphylococcus aureus infections. CG400549 is an antibiotic targeting fabI enoyl-(acyl carrier protein) reductase...
BioCentury | Oct 29, 2015
Product R&D

Qureing antibiotic resistance

...Gram-negative bacteria, filed for bankruptcy in June. Debiopharm Group is developing Debio 1452 , a fabI enoyl-(acyl carrier protein) reductase...
BioCentury | Jun 1, 2015
Clinical News

Debio 1450: Phase II started

...AFN-1720 ) Business: Infectious Molecular target: fabI enoyl-(acyl carrier protein) reductase Description: Small molecule prodrug inhibitor of the bacterial fabI enoyl-(acyl carrier protein) reductase...
BioCentury | Jun 1, 2015
Clinical News

Debio 1450: Phase II started

...Molecular target: fabI enoyl-(acyl carrier protein) reductase Description: Oral formulation of a small molecule prodrug inhibitor of the bacterial fabI enoyl-(acyl carrier protein) reductase...
BioCentury | Sep 22, 2014
Clinical News

Debio 1450 regulatory update

...bacterial skin and skin structure infections (ABSSSI). The small molecule prodrug inhibitor of the bacterial fabI enoyl-(acyl carrier protein) reductase...
BioCentury | Jun 23, 2014
Clinical News

oral Debio 1450: Phase I started

...Molecular target: fabI enoyl-(acyl carrier protein) reductase Description: Oral formulation of a small molecule prodrug inhibitor of the bacterial fabI enoyl-(acyl carrier protein) reductase...
Items per page:
1 - 10 of 24